Realising the potential of adaptive development of medicines.


The recent launch of a pilot scheme for 'adaptive licensing' by the European Medicines Agency could spell a new era in drug development. Rather than focusing on the purely regulatory aspect of the system, the proposals challenge several aspects of existing development processes, including the conventional roles of sponsor, regulatory and reimbursement… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.